Added to YB: 2025-10-06
Pitch date: 2025-10-02
OSE.PA [neutral]
OSE Immunotherapeutics SA
-49.58%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
Market Cap
EUR 72.9M
Pitch Price
EUR 7.10
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.37
P/E
-1.83
EV/Sales
32.17
Sector
Biotechnology
Category
turnaround
OSE Immunotherapeutics (OSE France): Board reshuffle clears the way for clinical focus
OSE.PA (quick overview): Board reshuffle complete w/ new CEO Alexis Peyroles & chairman Markus Cappel after months of governance disputes. Financing resolutions approved, providing capital flexibility for Phase IIb Lusvertikimab trials. Governance now stable, focus shifts to clinical execution & partnerships over next 12-18 months.
Read full article (1 min)